



EVITRADE Health Announces the Addition of Another Element to Its Vertically Integrated Services with a Non-Binding LOI with HEMP Extraction Technology Corp.

VANCOUVER, BC, Friday August 17, 2018 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB:AXHLF) (the “Company” or “EVITRADE”) announces the signing of a non-binding letter of intent (“LOI”) with HEMP Extraction Technology Corp. (HETC). HETC is an extraction technology company that is in the business of extracting medical grade oils from industrial hemp.

“We are pleased to be working with HETC and look forward to utilizing and implementing their extraction technology. Their technology and operational experience will enable the Company to develop our products in a more efficient manner and with supply security.” said C.K. Cheung, CEO of EVITRADE.

“This technology furthers the development of the molecular biological delivery and excipient carrier systems joint venture that the Company recently announced” continued C.K. Cheung; “We are excited to have this supply security lined up for the Company.”

Pursuant to the LOI with HETC, Evitrade has agreed to negotiate with HETC to complete a transaction (the “Proposed Transaction”) whereby Evitrade will acquire all of the outstanding share of HETC in exchange for an aggregate of 23,333,333 shares of Evitrade issued at the deemed price of \$0.30 per share. The result of the Proposed Transaction would be that HETC would become a wholly-owned subsidiary of Evitrade.

Management continues to strive to seek optimal business and commercialization strategies for the Company. Due to confidentiality provisions in the non-binding LOI, full details of the transaction will be available upon a final definitive agreement.

Contact: C.K. Cheung, CEO & Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcm Markets.com/stock/AXHLF/news>



About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency.

The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutraceutical Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcm Markets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.